Wu Bowen, Tan Li, Wang Weihua, Feng Xingzhong, Yan Dan
Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.
Diabetes Metab Syndr Obes. 2022 Jun 7;15:1715-1724. doi: 10.2147/DMSO.S362715. eCollection 2022.
Imidazole Propionate (ImP) is a new marker of Type 2 diabetes mellitus (T2DM), which can induce impaired glucose metabolism and weaken the efficacy of metformin. An extensive exploration into literature suggests that ImP may be associated with stool consistency.
Through an in-depth study of the relationship between stool consistency, bile acids, fecal microbiota and ImP, we intend to explore the mechanism driving the ImP content difference in T2DM.
This is a single-center, prospective, cross-sectional study. Plasma ImP and stool consistency were analyzed among 96 diabetic subjects and 45 healthy subjects. All subjects were divided into the stool consistency normal (N) group and the stool consistency abnormal group, of which the abnormal group was sub-divided into the hard stool (H) group and the soft stool (S) group. After identifying the correlation between ImP and stool consistency, we analyzed the influence of bile acids and fecal microbiota on ImP in diabetic subjects.
For T2DM patients, the ImP level of the abnormal stool consistency group was significantly higher than that of the normal stool consistency group ( < 0.001). Results were verified in 45 healthy subjects ( = 0.002). ImP was significantly associated with taurocholic acid (TCA) ( = 0.003) in feces, taurodeoxycholate (TDCA) ( = 0.003), glycochenodeoxycholate (GCDCA) ( = 0.021), and glycocholic acid (GCA) ( = 0.031) in plasma. The Shannon index of Group N was significantly higher than that of Group H ( = 0.041) and Group S ( = 0.003).
ImP was higher in diabetic patients with abnormal stool consistency than in those with normal stool consistency, which was related to the proportion of bile acids and fecal microbial structure. These findings may improve our understanding of ImP and contribute to the treatment of T2DM by improving stool consistency.
咪唑丙酸（ImP）是2型糖尿病（T2DM）的一种新标志物，它可导致糖代谢受损并削弱二甲双胍的疗效。对文献的广泛研究表明，ImP可能与粪便稠度有关。
通过深入研究粪便稠度、胆汁酸、粪便微生物群与ImP之间的关系，我们旨在探究T2DM中ImP含量差异的驱动机制。
这是一项单中心、前瞻性、横断面研究。对96例糖尿病患者和45例健康受试者的血浆ImP和粪便稠度进行了分析。所有受试者分为粪便稠度正常（N）组和粪便稠度异常组，其中异常组又分为硬便（H）组和软便（S）组。在确定ImP与粪便稠度之间的相关性后，我们分析了胆汁酸和粪便微生物群对糖尿病患者ImP的影响。
对于T2DM患者，粪便稠度异常组的ImP水平显著高于粪便稠度正常组（<0.001）。在45例健康受试者中验证了结果（=0.002）。ImP与粪便中的牛磺胆酸（TCA）（=0.003）、血浆中的牛磺脱氧胆酸（TDCA）（=0.003）、甘氨鹅脱氧胆酸（GCDCA）（=0.021）和甘胆酸（GCA）（=0.031）显著相关。N组的香农指数显著高于H组（=0.041）和S组（=0.003）。
粪便稠度异常的糖尿病患者的ImP高于粪便稠度正常的患者，这与胆汁酸比例和粪便微生物结构有关。这些发现可能会增进我们对ImP的理解，并通过改善粪便稠度有助于T2DM的治疗。
